Nasdaq News

Key PointsElon Musk has near-total control of Space Exploration Technologies' future.

(RTTNews) - Immix Biopharma (IMMX), on Tuesday reported that an interim update from the Phase 2 NEXICART-2 study showed an 89% complete response (CR) rate with investigational NXC-201 in patients with relapsed/refractory AL amyloidosis.

(RTTNews) - uniQure (QURE) reported additional data from its ongoing Phase I/II studies of ifezuntirgene inilparvovec (AMT-130) for the treatment of Huntington's disease.

(RTTNews) - Unicycive Therapeutics (UNCY) has resubmitted its New Drug Application (NDA) for oxylanthanum carbonate, seeking FDA approval of the oral phosphate binder for hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.

Key PointsArista Networks dominates the high-speed networking market for artificial intelligence data centers and cloud titans.

Key PointsInvestors don't need a six-figure portfolio balance before they can start generating income from their portfolios.

Key PointsChevron provides massive global scale and a strong balance sheet supported by integrated operations.

Key PointsCoca-Cola has raised its annual dividends for 64 consecutive years.

(RTTNews) - Pearson plc (PSO, PSON.L), a British learning and skill enterprise company, on Tuesday said it has agreed to acquire Workera, an AI intelligence platform focused on enterprise assessment and skills verification.

(RTTNews) - AT&T Inc. (T) on Tuesday said it has entered into a multi-year agreement with materials science company Corning Inc. (GLW), valued at more than $3 billion, for the supply of fiber and cable to support its network expansion and growing data demand.

Key PointsShares of Elon Musk's Space Exploration Technologies (SpaceX) went public in June, and have already lost 34% of their peak value.

(RTTNews) - Biotechnology company Unicycive Therapeutics, Inc. (UNCY) announced Tuesday the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company's investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with

(RTTNews) - Tuesday, uniQure (QURE) reported new data showing its investigational gene therapy AMT-130 continued to slow measures of Huntington's disease progression in patients followed for up to 48 months.

(RTTNews) - Tuesday, Kyowa Kirin (4151.T) said it entered into an exclusive distribution agreement with Knight Therapeutics (GUD.TO) for POTELIGEO (mogamulizumab) in select Latin American countries.

(RTTNews) - Carnival Corporation & plc (CCL) will host a conference call at 10:00 AM ET on September 29, 2026, to discuss Q3 26 earnings results.

Key PointsThe SEC is temporarily allowing some crypto companies to offer trading of tokenized stocks.

(RTTNews) - Stocks are likely to move to the upside in early trading on Tuesday, regaining ground following the weakness seen in the previous session. The major index futures are currently pointing to a modestly higher open for the markets, with the S&P 500 futures up by 0.2 perc

Key PointsBoth AT&T and T-Mobile offer yields that are far higher than the S&P 500 average.

Key PointsThe brand’s reputation has suffered due to substandard product innovation, leading Nike's fiscal 2026 revenue to be 9% below the total from three years ago.

(RTTNews) - Cartesian Therapeutics (RNAC) reported additional Phase 2 retreatment data for investigational Descartes-08 in generalized myasthenia gravis (MG), showing sustained improvements in disease symptoms 12 months after retreatment.